Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors

Angela Vasaturo, PhD; Senior Scientist, Ultivue
Julia Katerina Schwarze, MD; Dept of Medical Oncology, University Hospital Brussels

In this exciting webinar co-hosted by GEN and Clinical OMICs, we explored the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we heard how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.

Contact Us